10.26.16
Dr. Dhiraj Abhyankar has been appointed director of Scientific Development at Pharm-Olam International Ltd.
Dr. Abhyankar is a medical oncologist with more than 15 years of experience at both pharmaceutical companies and CROs. He previously held positions where he was responsible for clinical research on complex drugs, novel technology, 505B2 opportunities in oncology and a number of other therapeutics areas including respiratory, endocrinology and CNS. He also headed the team which conducted a clinical trial on the first global biosimilar monoclonal antibody.
“Dr. Abhyankar’s education and experience is a valuable addition to the Pharm-Olam team,” said Sanjiv Suri, Pharm-Olam’s chief executive officer. “Dr. Abhyankar has over a decade of experience in the development of oncology therapies in all phases of the development process. In his new role, he will play a critical part in providing strategic guidance for our clients’ early phase research, and provide medical support as treatments move through the development process. With oncology trials now comprising 25% of our total trial portfolio, the addition of Dr. Abhyankar comes at an important time.”
Pharm-Olam operates in more than 60 countries worldwide, offering clinical trial support for Phase I-IV clinical trials.
Dr. Abhyankar is a medical oncologist with more than 15 years of experience at both pharmaceutical companies and CROs. He previously held positions where he was responsible for clinical research on complex drugs, novel technology, 505B2 opportunities in oncology and a number of other therapeutics areas including respiratory, endocrinology and CNS. He also headed the team which conducted a clinical trial on the first global biosimilar monoclonal antibody.
“Dr. Abhyankar’s education and experience is a valuable addition to the Pharm-Olam team,” said Sanjiv Suri, Pharm-Olam’s chief executive officer. “Dr. Abhyankar has over a decade of experience in the development of oncology therapies in all phases of the development process. In his new role, he will play a critical part in providing strategic guidance for our clients’ early phase research, and provide medical support as treatments move through the development process. With oncology trials now comprising 25% of our total trial portfolio, the addition of Dr. Abhyankar comes at an important time.”
Pharm-Olam operates in more than 60 countries worldwide, offering clinical trial support for Phase I-IV clinical trials.